Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rituximab Treatment Timecourse on Primary B cells.

ABSTRACT: The data describe the treatment of a human Primary B cells. The cells were treated with Rituximab and the full untargeted proteomics and transcriptomics were profiled over a total of 6 timepoints (0,1,2,4,7,15) hours. A validation experiment was repeated as a separate experiment using a subset of the time points.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: George I. Mias

PROVIDER: MSV000081169 | MassIVE | Mon Jun 19 09:14:00 BST 2017

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

Integrated Transcriptomic and Proteomic Dynamics of Rituximab Treatment in B Lymphoblastoid Cells

Project description:The data describe the treatment of a human B cell lymphoblastoid cell line (B-LCL, line MS1). The cells were treated with Rituximab after 8 hours and the full untargeted proteomics and transcriptomics were profiled over a total of 24 hours, with samples acquired once every hour. A validation experiment was repeated as a separate experiment using a subset of the time points.

2016-10-13 | MSV000080244 | MassIVE

Everolimus Treatment of B Lymphoblastoid Cell Line Timecourse (24 timepoints)

Project description:The data describe longitudinal profiling, pre and post treatment of a human B lymphoblastoid cell line (B-LCL). The cells were treated with Everolimus at timepoint 7 and the full untargeted proteomics and transcriptomics were profiled over a total of 24 timepoints (over 12 hours), with samples acquired once every half-hour. A validation experiment was repeated as a separate experiment using a subset of the time points.

2017-06-19 | MSV000081170 | MassIVE

Transcription profiling of yeast wild type strain DBY7286 and crz1D strain YHY804 exposed to CaCl2

Project description:Wild-type strain DBY7286 and the crz1D strain YHY804 were cultured and exposed to CaCl2 as described for Experiments 1 and 2. Samples were collected at 15 and 30 min after Ca2+ addition. For the publication, the experiment was repeated twice, and corresponding timepoints were averaged between the experiments. The first two arrays and last two arrays in this set correspond to the separate experiments.

2005-01-01 | E-SMDB-10 | biostudies-arrayexpress

Meleagris gallopavo

Project description:TSKMLO microarray validation experiment

| PRJNA120313 | ENA

Genome-wide transcription analysis of whole blood prior to rituximab treatment in relation to clinical response

Project description:B cell depletion therapy is efficacious in RA patients failing on TNF blocking agents. However, approximately 40-50% of the rituximab-treated RA patients have a poor response. We investigated wheter baseline gene expression levels can discriminate between clinical nonresponders and responders to rituximab Whole blood total RNA is isolated from PAXgene tubes obtained prior to start of rituximab treatment

2012-04-09 | E-GEOD-37107 | biostudies-arrayexpress

Transcription profiling of human chronic lymphocytic leukemia samples to improve prognosis and predict therapeutic response

Project description:Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy, characterized by a variable clinical course. While clinical and laboratory parameters are increasingly being used to refine prognosis, they do not accurately predict response to commonly used therapy. We used gene expression profiling to generate and further refine prognostic and predictive markers. Genomic signatures that reflect progressive disease and responses to chemotherapy or chemo-immunotherapy were created using cancer cell lines and patient leukemia samples. We validated these signatures using independent clinical data from four separate cohorts representing a total of 301 CLL patients. A prognostic genomic signature created from patient leukemic cell gene expression data coupled with clinical parameters could statistically differentiate patients with stable or progressive disease in the training dataset. The progression signature was then validated in two independent datasets, demonstrating a capacity to accurately identify patients at risk for progressive disease. In addition, two distinct genomic signatures that predict response to chlorambucil or pentostatin, cyclophosphamide, and rituximab were also generated and were shown to accurately distinguish responding and non-responding CLL patients. Microarray analysis of CLL patientsâ lymphocytes can be used to refine prognosis and predict response to different therapies. These results have direct implications for standard and investigational therapeutics in CLL patients. Experiment Overall Design: For the predictive genomic signature or response to pentostatin, cyclophosphamide, and rituximab, 20 CLL leukemia samples were used in the training set, and 20 CLL leukemia samples were used in the validation set

2009-11-11 | E-GEOD-10137 | biostudies-arrayexpress

Integrated Transcriptomic and Proteomic Dynamics of Rituximab Treatment in Primary B Cells

Project description:The investigation aims to profile the molecular dynamics of Rituximab treatment in cells. Specifically, primary B cells were treated with Rituximab, and sampled across 6 time points. Treated and untreated cells were processed to extract RNA and protein, that were subsequently used in high-throughput analysis of the transcriptome (RNA-Sequencing) and proteome (mass spectrometry).

2018-10-13 | GSE100441 | GEO

Danio rerio

Project description:Experiment 4: Affymetrix validation array

| PRJNA123377 | ENA

Genome-wide transcription analysis of whole blood prior to rituximab treatment in relation to clinical response

2019-09-10 | GSE37107 | GEO

138ff350-f3cd-4e2f-8310-4592f0a3fed2 - samples

Project description:This dataset contains log2(TPM + 1) for 271 tumor samples profiled by RNA-seq for the subset of genes used for validation of the NMF cluster assignments.

| EGAD00001006928 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data